Linda Eriksson1,2, Agneta Wennman-Larsen3,4, Karin Bergkvist5,4, Per Ljungman6,7, Jeanette Winterling5,8. 1. Department of Neurobiology, Care Sciences and Society, Division of Nursing, Karolinska Institutet, Alfred Nobels allé 23, C4, 141 52, Stockholm, Sweden. linda.eriksson@ki.se. 2. Department of Haematology, Karolinska University Hospital, Stockholm, Sweden. linda.eriksson@ki.se. 3. Department of Clinical Neuroscience, Division of Insurance Medicine, Karolinska Institutet, Stockholm, Sweden. 4. Sophiahemmet University, Stockholm, Sweden. 5. Department of Neurobiology, Care Sciences and Society, Division of Nursing, Karolinska Institutet, Alfred Nobels allé 23, C4, 141 52, Stockholm, Sweden. 6. Department of Medicine Huddinge, Division of Haematology, Karolinska Institutet, Stockholm, Sweden. 7. Department of Cellular Therapy and Allogeneic Stem Cell Transplantation, Karolinska University Hospital Huddinge, Stockholm, Sweden. 8. Department of Haematology, Karolinska University Hospital, Stockholm, Sweden.
Abstract
PURPOSE: This study examines sick leave (SL) and factors associated with full-time SL 1 year after allogeneic haematopoietic stem cell transplantation (allo-HSCT) in patients of working age from 2009 to 2016 (n = 122). METHODS: Questionnaire data were collected on admission to the allo-HSCT unit, at 7 months and 1 year after allo-HSCT. Associations between factors and SL were analysed using logistic regression analyses. RESULTS: One year after allo-HSCT, 76% of participants were on SL, with 36% on full-time SL. In univariable analyses, chronic graft-versus-host-disease (cGvHD) (OR 3.07; 95% CI 1.34-7.07; p = 0.01), having symptoms of depression at 7 months (OR 4.81; 95% CI 1.69-13.69; p = 0.00) and low levels of vocational satisfaction at 7 months after treatment (OR 3.27; 95% CI 1.27-8.41; p = 0.01) were associated with full-time SL 1 year after allo-HSCT. cGvHD (OR 3.43; 95% CI 1.35-8.73; p = 0.01) and having symptoms of depression at 7 months after allo-HSCT (OR 3.37; 95% CI 1.2-11.58; p = 0.02) remained significant in multivariable analysis. CONCLUSION: The majority of allo-HSCT survivors were on SL 1 year after treatment, and cGvHD, low vocational satisfaction and depressive symptoms were associated with full-time SL 1 year after allo-HSCT. IMPLICATIONS FOR CANCER SURVIVORS: Healthcare professionals need to be observant of and manage the consequences of cGvHD and patients' symptoms of depression in order to support them appropriately in their return-to-work process.
PURPOSE: This study examines sick leave (SL) and factors associated with full-time SL 1 year after allogeneic haematopoietic stem cell transplantation (allo-HSCT) in patients of working age from 2009 to 2016 (n = 122). METHODS: Questionnaire data were collected on admission to the allo-HSCT unit, at 7 months and 1 year after allo-HSCT. Associations between factors and SL were analysed using logistic regression analyses. RESULTS: One year after allo-HSCT, 76% of participants were on SL, with 36% on full-time SL. In univariable analyses, chronic graft-versus-host-disease (cGvHD) (OR 3.07; 95% CI 1.34-7.07; p = 0.01), having symptoms of depression at 7 months (OR 4.81; 95% CI 1.69-13.69; p = 0.00) and low levels of vocational satisfaction at 7 months after treatment (OR 3.27; 95% CI 1.27-8.41; p = 0.01) were associated with full-time SL 1 year after allo-HSCT. cGvHD (OR 3.43; 95% CI 1.35-8.73; p = 0.01) and having symptoms of depression at 7 months after allo-HSCT (OR 3.37; 95% CI 1.2-11.58; p = 0.02) remained significant in multivariable analysis. CONCLUSION: The majority of allo-HSCT survivors were on SL 1 year after treatment, and cGvHD, low vocational satisfaction and depressive symptoms were associated with full-time SL 1 year after allo-HSCT. IMPLICATIONS FOR CANCER SURVIVORS: Healthcare professionals need to be observant of and manage the consequences of cGvHD and patients' symptoms of depression in order to support them appropriately in their return-to-work process.
Authors: Jeanette Winterling; Eva Johansson; Lena Wettergren; Per Ljungman; Kristina Alexanderson Journal: Eur J Cancer Care (Engl) Date: 2018-01-08 Impact factor: 2.520
Authors: P van Muijen; N L E C Weevers; I A K Snels; S F A Duijts; D J Bruinvels; A J M Schellart; A J van der Beek Journal: Eur J Cancer Care (Engl) Date: 2012-12-26 Impact factor: 2.520
Authors: C Ferry; G Gemayel; V Rocha; M Labopin; H Esperou; M Robin; R P de Latour; P Ribaud; A Devergie; T Leblanc; E Gluckman; A Baruchel; G Socié Journal: Bone Marrow Transplant Date: 2007-05-28 Impact factor: 5.483
Authors: Eleshia J Morrison; Shawna L Ehlers; Carrie A Bronars; Christi A Patten; Tabetha A Brockman; James R Cerhan; William J Hogan; Shahrukh K Hashmi; Dennis A Gastineau Journal: Biol Blood Marrow Transplant Date: 2016-05-21 Impact factor: 5.742
Authors: Carol Cancelliere; James Donovan; Mette Jensen Stochkendahl; Melissa Biscardi; Carlo Ammendolia; Corrie Myburgh; J David Cassidy Journal: Chiropr Man Therap Date: 2016-09-08